What it is
Rezafungin is an antifungal drug of the echinocandin class. Its label calls rezafungin acetate "a semisynthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans" — a ring of modified amino acids carrying a long side chain, which in rezafungin is a three-ring terphenyl ending in a pentyloxy group. The label's chemical name starts from echinocandin B, the same natural starting molecule as anidulafungin, with a trimethylammonio-ethoxy group added to one of the ring's ornithines.
| Property | Value | Source |
|---|---|---|
| Salt in the vial | rezafungin acetate, C63H85N8O17·C2H3O2 | label |
| Formula weight | 1,285.46 g/mol (acetate) · 1,226.4 (ion) | label · PubChem CID 78318119 |
| Per vial | 210 mg acetate = 200 mg rezafungin | label |
| Class | echinocandin | label |
The library's echinocandins entry sets it beside the three older members of the class, caspofungin, micafungin and anidulafungin.
How it works
Echinocandins inhibit the synthesis of 1,3-β-D-glucan, a sugar polymer the fungal cell wall needs (label, section 11). What sets rezafungin apart is how long it stays: the label's population model gives a terminal half-life of 152 ± 29 hours in patients — about six days — with no hepatic metabolism observed and protein binding of 87.5–93.6% in patients. Exposure in patients with candidemia was about 30% lower than in healthy volunteers.
That half-life is why the label's schedule is one 400 mg infusion, then 200 mg once a week, where caspofungin in the comparison trial was given every day. The label adds that safety has not been established beyond four weekly doses.
What the evidence shows
The US approval rests on one randomised, double-blind trial (Trial 1, ReSTORE, NCT03667690) against caspofungin (70 mg once, then 50 mg daily), in patients with candidemia or invasive candidiasis. 199 were randomised; 187 with a confirmed Candida culture formed the main analysis. Median treatment was 14 days in both arms.
| Outcome (label Table 4) | Rezafungin, n = 93 | Caspofungin, n = 94 | Difference (95% CI) |
|---|---|---|---|
| All-cause death by day 30 | 22 (23.7%) | 20 (21.3%) | 2.4 (−9.7 to 14.4) |
| Global cure, day 5 | 52 (55.9%) | 49 (52.1%) | 3.8 (−10.5 to 17.9) |
| Global cure, day 14 | 55 (59.1%) | 57 (60.6%) | −1.5 (−15.4 to 12.5) |
| Investigator clinical cure, day 5 | 59 (63.4%) | 70 (74.5%) | −11.0 (−24.0 to 2.3) |
The arms finished close together, but the intervals are wide — the trial was too small to rule out a difference of about ten points either way, and the label's own wording is that approval is "based on limited clinical safety and efficacy data." The common Candida species were C. albicans (42%), C. glabrata (26%), C. tropicalis (20%) and C. parapsilosis (13%).
The safety set covers 76 volunteers in phase 1 and 232 patients in two trials; reactions in 5% or more were low potassium, fever, diarrhoea, anaemia, vomiting, nausea, low magnesium, abdominal pain, constipation and low phosphate. The warnings section lists hypersensitivity including anaphylaxis, infusion reactions (flushing, warmth, hives, chest tightness), photosensitivity, and liver-test abnormalities.
What is not established: prevention. A phase 3 prophylaxis trial in stem-cell transplant recipients (ReSPECT, NCT04368559, 602 participants) is listed as completed, but the US label carries no prevention indication, and this entry did not open its results. Trials in Pneumocystis pneumonia and chronic pulmonary aspergillosis are registered as phase 2.
Where it stands
Rezafungin was approved in the US on 22 March 2023 as Rezzayo (NDA 217417); the current label (effective 2026-07-01) names Melinta Therapeutics. It is indicated for adults and children 12 and older with limited or no alternative options, and has not been studied in Candida endocarditis, osteomyelitis or meningitis. It is an infusion-only hospital drug.
Sources opened 2026-11-18: Rezzayo label (openFDA, effective 2026-07-01: sections 1, 2, 5, 6, 11, 12.3, 14); Drugs@FDA NDA 217417; PubChem CID 78318119; ClinicalTrials.gov API v2 (11 records incl. NCT03667690, NCT04368559, NCT06774144, NCT05835479, NCT06794554); PubMed E-utilities counts.
